Catalyst Pharmaceuticals (CPRX) is a publicly traded Healthcare sector company. As of July 10, 2026, CPRX trades at $31.48 with a market cap of $3.85B and a P/E ratio of 17.39. CPRX moved +0.03% today. Year to date, CPRX is +34.83%; over the trailing twelve months it is +45.53%. Its 52-week range spans $19.05 to $32.56. Analyst consensus is neutral with an average price target of $32.40. Rallies surfaces CPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Catalyst Pharmaceuticals to Exit S&P SmallCap 600 on July 15 After Angelini Deal: Catalyst Pharmaceuticals will be deleted from the S&P SmallCap 600 before market open on July 15, 2026, when Solaris Energy Infrastructure takes its place. The removal follows Angelini Pharma’s pending acquisition of Catalyst, which is expected to close soon subject to final conditions.
| Metric | Value |
|---|---|
| Price | $31.48 |
| Market Cap | $3.85B |
| P/E Ratio | 17.39 |
| EPS | $1.81 |
| Dividend Yield | 0.00% |
| 52-Week High | $32.56 |
| 52-Week Low | $19.05 |
| Volume | 901.09K |
| Avg Volume | 0 |
| Revenue (TTM) | $596.96M |
| Net Income | $221.32M |
| Gross Margin | 85.96% |
6 analysts cover CPRX: 0 strong buy, 1 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $32.40.